GSK Turkey

Last updated: 27.07.2015

Glaxosmithkline has been present in Turkey for more than 50 years, and today is the sixth largest vendor of pharmaceutical products in the country. Istanbul has served as a hub for the pharmaceutical division in the MENA-CIS region since 2012, with a regional-level staff of 30 people of various nationalities; the consumer health division regional HQ will be moved to Turkey by the end of Q1 2016. Overall, GSK Turkey employs over 800 people across pharmaceuticals and consumer health business units.

GSK has made several large investments in the Turkish market, including the only Vaccine Clinical Research Center (AKAM) in Turkey, established in 2010 in Ankara. Over USD 21.5 million has been invested thus far in partnership with a CMO partner for the production of five different antigens, targeting a local production of 33 million doses per year, and two of these will be produced beginning at the formulation level.

Within pharmaceuticals, GSK Turkey has three main business units; respiratory, classical brands and vaccines and critical diseases. Major brands by unit and team include;

  • Respiratory: Seretide, Flixotide
  • Classical Brands (mainly focuses on classic brands and dermatology):
    • Urology & CNS: Avodart, Lamictal, Paxil
    • Dermatology: Clindoxyl/Isotrexin, Valtrex, Vate Family, Bactroban, Zovirax
    • GP: Augmentin, Sterimar, Paxil, Flixotide
  • Vaccines and Critical Diseases
    • Vaccines: Rotarix, Cervarix, Fluarix Tetra, Engerix, Boostrix, Nimenrix
    • Critical Diseases: Volibris

GSK Turkey will launch 9 new products from the pipeline between 2016 and 2019.

Contact Details
Büyükdere Cad. 1. Levent Plaza No:173 B Blok
34394 Levent İstanbul
(0212) 339 44 00 – 339 45 75
GSK Türkiye Call Center: 444 5 GSK (444 5 475)



We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here